Baric Lab 改造了SARS病毒 同时研制了瑞德西韦。要不要用同样的阴谋论讨论一下这个实验室？ https://www.the-scientist.com/news-opinion/lab-made-coronavirus-triggers-debate-34502?archived_content=9BmGYHLCH6vLGNdd9YzYFAqV8S3Xw3L5 Ralph Baric, an infectious-disease researcher at the University of North Carolina at Chapel Hill, last week (November 9) published a study on his team’s efforts to engineer a virus with the surface protein of the SHC014 coronavirus, found in horseshoe bats in China, and the backbone of one that causes human-like severe acute respiratory syndrome (SARS) in mice. The hybrid virus could infect human airway cells and caused disease in mice, according to the team’s results, which were published in Nature Medicine . The results demonstrate the ability of the SHC014 surface protein to bind and infect human cells, validating concerns that this virus—or other coronaviruses found in bat species—may be capable of making the leap to people without first evolving in an intermediate host, Nature reported. They also reignite a debate about whether that information justifies the risk of such work, known as gain-of-function research. “If the [new] virus escaped, nobody could predict the trajectory,” Simon Wain-Hobson, a virologist at the Pasteur Institute in Paris, told Nature . In October 2013, the US government put a stop to all federal funding for gain-of-function studies, with particular concern rising about influenza, SARS, and Middle East respiratory syndrome (MERS). “NIH [National Institutes of Health] has funded such studies because they help define the fundamental nature of human-pathogen interactions, enable the assessment of the pandemic potential of emerging infectious agents, and inform public health and preparedness efforts,” NIH Director Francis Collins said in a statement at the time. “These studies, however, also entail biosafety and biosecurity risks, which need to be understood better.” Baric’s study on the SHC014-chimeric coronavirus began before the moratorium was announced, and the NIH allowed it to proceed during a review process, which eventually led to the conclusion that the work did not fall under the new restrictions, Baric told Nature . But some researchers, like Wain-Hobson, disagree with that decision. The debate comes down to how informative the results are. “The only impact of this work is the creation, in a lab, of a new, non-natural risk,” Richard Ebright, a molecular biologist and biodefence expert at Rutgers University, told Nature . But Baric and others argued the study’s importance. “[The results] move this virus from a candidate emerging pathogen to a clear and present danger,” Peter Daszak, president of the EcoHealth Alliance, which samples viruses from animals and people in emerging-diseases hotspots across the globe, told Nature . https://endeavors.unc.edu/fighting-emerging-diseases-at-unc/ A model platform for an academic-corporate partnership,Gilead Sciences, Inc.and UNC are teaming up to save lives. The biopharmaceutical company sought the resources and talents of theUNC Gillings School of Global Public Health’sBaric Lab in the development of treatments with the power to control outbreaks of disease. Ralph Baric, head of the lab and professor of epidemiology, has pioneered rapid-response approaches for the study of emerging viruses and the development of therapeutics. The lab was a natural fit when it came time to test a treatment with promise to work against multiple coronaviruses, a family of viruses that primarily infect the upper respiratory and gastrointestinal tract. The treatment is a broad-spectrum antiviral — it works against a large variety of viral pathogens — and is a potential key to pandemic preparedness. The increasing interconnectedness of our world makes it easy for sick people in seemingly remote areas to spread emerging viral diseases throughout the globe. The Gilead broad-spectrum treatment that was tested and proven in the Baric Lab, now known as Remdesivir , has been deployed for use in the current Ebola outbreak in the Democratic Republic of the Congo. Not only does the drug have potential to save lives there, but all efficacy and safety results will inform treatments for other coronaviruses.
In October 2013, the US government put a stop to all federal funding for gain-of-function studies, with particular concern rising about influenza, SARS, and Middle East respiratory syndrome (MERS).
A new strain of coronavirus is spreading faster than anticipated, with at least 80 deaths and thousands of people sickened since the outbreak began in Wuhan, China. The answer to fighting it could be in the Triangle
https://sph.unc.edu/event/virology-in-progress-a-mini-symposium-on-the-newly-emerging-coronavirus/ 他这个月7号要开讲座， 支持在线观看 A Mini-Symposium on the Newly Emerging Coronavirus Learn more about the 2019 Novel Coronavirus and the research being done by UNC’s world-class faculty to combat it. Featuring presentations by Dr. Ralph Baric, Dr. Shuntai Zhou and Dr. David Weber Friday, Feb. 7 1:30-3 p.m. EST This event will be available to stream live via WebEx. Join the stream （在线链接在最上面的网页里） Meeting number (access code): 733 519 494 Meeting Password: symposium
I am so scarred by you. I am just guessing and commenting. I do not work for any party nor against any... You talked just like that aggressive biochemical weapon.
Ralph Baric, an infectious-disease researcher at the University of North Carolina at Chapel Hill, last week (November 9) published a study on his team’s efforts to engineer a virus with the surface protein of the SHC014 coronavirus, found in horseshoe bats in China, and the backbone of one that causes human-like severe acute respiratory syndrome (SARS) in mice. The hybrid virus could infect human airway cells and caused disease in mice, according to the team’s results, which were published in Nature Medicine. The results demonstrate the ability of the SHC014 surface protein to bind and infect human cells, validating concerns that this virus—or other coronaviruses found in bat species—may be capable of making the leap to people without first evolving in an intermediate host, reported. They also reignite a debate about whether that information justifies the risk of such work, known as gain-of-function research. “If the [new] virus escaped, nobody could predict the trajectory,” Simon Wain-Hobson, a virologist at the Pasteur Institute in Paris, told Nature. In October 2013, the US government all federal funding for gain-of-function studies, with particular concern rising about influenza, SARS, and Middle East respiratory syndrome (MERS). “NIH [National Institutes of Health] has funded such studies because they help define the fundamental nature of human-pathogen interactions, enable the assessment of the pandemic potential of emerging infectious agents, and inform public health and preparedness efforts,” NIH Director Francis Collins said in a statement at the time. “These studies, however, also entail biosafety and biosecurity risks, which need to be understood better.” Baric’s study on the SHC014-chimeric coronavirus began before the moratorium was announced, and the NIH allowed it to proceed during a review process, which eventually led to the conclusion that the work did not fall under the new restrictions, Baric told Nature. But some researchers, like Wain-Hobson, disagree with that decision. The debate comes down to how informative the results are. “The only impact of this work is the creation, in a lab, of a new, non-natural risk,” Richard Ebright, a molecular biologist and biodefence expert at Rutgers University, told Nature. But Baric and others argued the study’s importance. “[The results] move this virus from a candidate emerging pathogen to a clear and present danger,” Peter Daszak, president of the EcoHealth Alliance, which samples viruses from animals and people in emerging-diseases hotspots across the globe, told Nature. https://endeavors.unc.edu/fighting-emerging-diseases-at-unc/ A model platform for an academic-corporate partnership, Gilead Sciences, Inc. and UNC are teaming up to save lives. The biopharmaceutical company sought the resources and talents of the UNC Gillings School of Global Public Health’s Baric Lab in the development of treatments with the power to control outbreaks of disease. Ralph Baric, head of the lab and professor of epidemiology, has pioneered rapid-response approaches for the study of emerging viruses and the development of therapeutics. The lab was a natural fit when it came time to test a treatment with promise to work against multiple coronaviruses, a family of viruses that primarily infect the upper respiratory and gastrointestinal tract. The treatment is a broad-spectrum antiviral — it works against a large variety of viral pathogens — and is a potential key to pandemic preparedness. The increasing interconnectedness of our world makes it easy for sick people in seemingly remote areas to spread emerging viral diseases throughout the globe. The Gilead broad-spectrum treatment that was tested and proven in the Baric Lab, now known as Remdesivir, has been deployed for use in the current Ebola outbreak in the Democratic Republic of the Congo. Not only does the drug have potential to save lives there, but all efficacy and safety results will inform treatments for other coronaviruses.
I am so scarred by you. I am just guessing and commenting. I do not work for any party nor against any... You talked just like that aggressive biochemical weapon. AaaaMei 发表于 2/6/2020 2:51:00 PM
石正丽和Baric的论文：https://www.nature.com/articles/nm.3985?fbclid=IwAR0iTTfDlT-uxNFPtvQH-xFrF6QaF1hKE1Ey2TPrEi17XfFUElbpUlAosDc
洗白文：http://wap.sciencenet.cn/blog-404304-1217130.html?mobile=1 中提及的1/23日的新论文： https://www.biorxiv.org/content/10.1101/2020.01.22.914952v2
然后通过治病救人来收买人心然后加以利用的感觉
这个是纯粹为了卖药赚钱？
那为层主带节奏
gilead又不是tsla
上天有好生之德。这么大的全球瘟疫当然会有神力来帮人。中国老百姓这样受苦，有投毒的就有解毒，这个世界不是二元对立而是正负相连，有为名为利害人的就有不求回报帮人的。
Trump不杀那一个头，百姓和兵会死的更多。明明本来签署的中美协议要延期了，谁是受益者？土共苦肉计演太多了，当初和苏联闹翻结果让百姓勒紧裤腰带还债。
土共研究病毒还敢发文章申请专利，保留六万多毒株，敢这样做还不会引起别人关注？
你这样颠倒黑白是非，发帖子没几毛，替血债累累的土共说话不怕瘟神找你吗？
I am so scarred by you. I am just guessing and commenting. I do not work for any party nor against any... You talked just like that aggressive biochemical weapon.
So do you
好多信息
居然只偷病毒，没偷解药。
Chiglish 有什么关系？我本来就是中国来的，和你一样啊，要不然就不在这华人网混了。不像有些人，真心以为自己是地道得美国人了，在这里骂一骂中国，就假装不是中国来的啦
见过皮厚的，没见过皮像你这么厚的。难怪是五毛，专业素质到人品就一个字-烂！
喜欢阴阳怪气嘲讽美籍华人把“真心以为自己是地道美国人”彻底暴露了你。只有国内那些酸葡萄，和你这种带任务的五毛最喜欢这么说美华。别装了！
还有，别自作多情说自己跟其他网友一样。谁跟你一样low??? 中国出生的就都一样啊？！你也配？我呸吧你！
你怎么就知道我是五毛？我自己就是美籍华人，我为什么嘲讽自己？还有请不要这样泼妇骂街
2013年5月，石正丽组和美国纽约的一个NGO的合作项目，
发现中国境内某种蝙蝠携带类似SARS病毒，以此投稿到Nature,
9月份接收，10月出版。论文地址
https://www.nature.com/articles/nature12711
2015年6月，北卡的研究组利用石的病毒样本，合成一种新的冠状病毒。
具有全部活性，可传人，已知的治疗手段都不管用。这个合成病毒是用2013年石正丽
发现的蝙蝠天然病毒中的spike protein替换2003年的SARS-CoV中的S蛋白，
是个嵌合体，这个新的人造病毒命名是SHC014-CoV。
https://www.nature.com/articles/nm.3985?fbclid=IwAR0iTTfDlT-uxNFPtvQH-xFrF6QaF1hKE1Ey2TPrEi17XfFUElbpUlAosDc
已知最早人工合成新冠的，有论文出处的是北卡研究组。北卡发的文章10多个作者石只排倒数第2。当时这文章一发表就引起巨大争议，项目据说被叫停，最后是否继续完成就不得而知了。
Remdesivir也是北卡组的Ralph Baric领导的小组与Gilead合作研究的药物，一期临床
也是在北卡做的。
这些信息怎么解读就看个人了。
顺着思路，虽然美国的被叫停了，但被弯道超车们偷回国，继续搞实验，结果实验室管理不善，泄露了，然后把锅扣回亡我之心，逻辑上很通顺